|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
DETREND PRICE OSCILLATOR
Trading: SELL @ $169.55
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Amgen (NASDAQ:AMGN) currently has a confirmed downtrend. Price is currently below the displaced moving average for AMGN Currently, the return on DPO20 is -0.2%.
The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.
Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;
PROFILE: Amgen (AMGN)
Stock Exchange: NASDAQ
Ticker Codes: | AMGN | NASDAQ:AMGN |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
|OSTK OverstockCom Inc||11.57||15.5||12,377,998||0.78||BULLISH|
|BLCM Bellicum Pharma||2.22||8.8||532,809||1.1||BULLISH|
|FRAN Francesca'S Holdings||0.42||4.3||1,320,085||2.51||BULLISH|
|PGNX Progenics Pharmaceuticals||5.2||4.2||1,906,730||0.01||BULLISH|
|AMAG Amag Pharmaceuticals||8.97||4.1||2,022,834||4.49||BULLISH|
|FARO Faro Tech Inc||51.43||3.5||704,798||3.11||BULLISH|
|SCWX Secureworks Corp||14.24||3.5||929,147||1.54||BULLISH|